Literature DB >> 29413498

Diagnostic performances of the Xpert MTB/RIF in Brazil.

Denise Rossato Silva1, Giovanni Sotgiu2, Lia D'Ambrosio3, Giovana Rodrigues Pereira4, Márcia Silva Barbosa5, Natan José Dutra Dias6, Laura Saderi7, Rosella Centis8, Giovanni Battista Migliori9.   

Abstract

BACKGROUND AND OBJECTIVES: As for all tests, the diagnostic performances of Xpert MTB/RIF might be different in settings with different tuberculosis prevalence. Aim of the study is to evaluate the performances of Xpert MTB/RIF to diagnose tuberculosis in Brazil, where 407 culture-confirmed tuberculosis patients were retrospectively enrolled in Rio Grande do Sul, between 2015 and 2016.
METHODS: Sensitivity, specificity, positive and negative predictive values of the test were calculated and a logistic regression analysis was performed to assess the role played by explanatory variables in the occurrence of true positive and negative diagnostic results.
RESULTS: Sensitivity of Xpert MTB/RIF was 100.0%, specificity 92.8%; positive and negative predictive values were 71.4% and 100.0%, respectively. In the HIV- infected sub-group specificity was 59.3%. In the multivariate logistic regression analysis, true positivity was associated with increasing age (1.0; p-value: 0.02) while true positivity and negativity were negatively associated with alcohol abuse.
CONCLUSIONS: Xpert is sensitive and specific in the Brasilian settings.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brazil; Diagnosis; HIV; Tuberculosis; Xpert MTB/RIF

Mesh:

Substances:

Year:  2017        PMID: 29413498     DOI: 10.1016/j.rmed.2017.11.012

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

2.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

3.  Eliminating tuberculosis in Latin America: making it the point.

Authors:  Raquel Duarte; Denise Rossato Silva; Adrian Rendon; Tatiana Galvẫo Alves; Marcelo Fouad Rabahi; Rosella Centis; Afrânio Kritski; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2018-04       Impact factor: 2.624

4.  Tuberculosis series 2019.

Authors:  Denise Rossato Silva; Giovanni Battista Migliori; Fernanda Carvalho de Queiroz Mello
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

5.  Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil.

Authors:  Cinara Silva Feliciano; Lucas José Bazzo Menon; Livia Maria Pala Anselmo; Anzaan Dippenaar; Robin Mark Warren; Wilson Araújo Silva; Valdes Roberto Bollela
Journal:  ERJ Open Res       Date:  2019-08-05

6.  International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis.

Authors:  Giovanni Battista Migliori; Rosella Centis; Lia D'Ambrosio; Denise Rossato Silva; Adrian Rendon
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

7.  Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: The example of RePORT Brazil.

Authors:  María B Arriaga; Gustavo Amorim; Artur T L Queiroz; Moreno M S Rodrigues; Mariana Araújo-Pereira; Betania M F Nogueira; Alexandra Brito Souza; Michael S Rocha; Aline Benjamin; Adriana S R Moreira; Jamile G de Oliveira; Marina C Figueiredo; Megan M Turner; Kleydson Alves; Betina Durovni; José R Lapa-E-Silva; Afrânio L Kritski; Solange Cavalcante; Valeria C Rolla; Marcelo Cordeiro-Santos; Timothy R Sterling; Bruno B Andrade
Journal:  Int J Infect Dis       Date:  2020-11-14       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.